TRPC3 is a non-selective cation channel, which forms a Ca 2+ entry pathway involved in cardiac remodelling. Our aim was to analyse acute electrophysiological and contractile consequences of TRPC3 activation in the heart.
Introduction
Hypertrophic remodelling of the myocardium is typically initiated by stimuli originating from either release of neuroendocrine factors such as angiotensin II (AngII), 1 endothelin I, 2 and noradrenalin 3 or by exaggerated mechanical strain. 4 These pathogenic stimuli trigger cellular Ca 2+ signals that modify gene expression to restructure the myocardium.
The pivotal signalling role of Ca 2+ in cardiac remodelling is well established 5, 6 and involves spatial linkage between Ca 2+ entry channels and Ca 2+ -dependent signalling molecules, such as calmodulin-dependent protein kinase II (CaMKII), 7 PKC, 8 and calcineurin (CaN). 9, 10 A critical step in the early stage of cardiac remodelling is up-regulation of the expression of certain Ca 2+ channel proteins to modify cardiac Ca 2+ homeostasis and Ca 2+ -transcription coupling. Some Ca 2+ channels, such as voltage-gated L-type channels (Ca V 1.2), are capable of serving both normal excitation-contraction as well as excitation-transcription coupling. In contrast, voltage-insensitive channels are considered to control preferentially Ca 2+ signals that activate gene transcription. Initiation of Ca 2+ -dependent processes of transcriptional regulation is likely to take place in specialized regulatory microdomains that are somehow segregated from the oscillatory rise and fall in cytoplasmic Ca 2+ , as associated with excitation-contraction coupling. 1,5,11 -14 TRPC channels were found up-regulated in response to mechanical stress-associated afterload 2,15 -17 or increased neurohumoural stimuli. 1, 3, 15, 16 TRPC3 has been demonstrated to supply Ca 2+ in a highly efficient and selective manner for CaN regulation, 4, 12 which requires minute membrane currents and is not associated with global cytoplasmic Ca 2+ . Nonetheless, non-selective cation conductances, as generated by TRPC channels, are expected to impact on excitability and contractile function of cardiomyocytes. Nonetheless, the consequences of acute activation of cardiac TRPC channels, especially in conditions of enhanced expression such as cardiac hypertrophy or heart failure, are so far unclear, and the role of non-selective cation conductances in cardiac dysfunction during remodelling is incompletely understood. Previous studies 17 -20 in neonatal and adult cardiac cells suggested negligible involvement of TRPC3 in excitation-contraction coupling. TRPC3 channels display only weak Ca 2+ over Na + permeability (Ca 2+ :Na + ¼ 1.6) and a characteristic double-rectifying current to voltage feature, thus allowing for significant Na + loading and depolarization during diastole. Hence, activation of this conductance is expected to generate significant disturbances in action potential morphology and to simultaneously shift equilibrium and operation of electrogenic Na + transport specifically of NCX1, which has repeatedly been demonstrated as a signalling partner of TRPC channels in muscle cells. 7, 21, 22 Analysis of acute functional consequences of TRPC3 is limited by its complex mechanism of activation, which typically involves stimulation of phospholipase C and thereby several routes linked to excitation -contraction coupling. Availability of a direct small molecule activator of TRPC3 (GSK1702934A) prompted experiments to identify the acute consequences of TRPC3 activation in a murine model of cardiac overexpression and to compare its functional effects with that of AngII , a classical mediator activating TRPC conductances. With this study, we demonstrate that TRPC3 is a determinant of cardiac contractility and excitability. This function of TRPC3 is based on its interaction with NCX1, which translates TRPC3 activity into altered cellular Ca 2+ handling and action potential morphology.
Methods

GSK synthesis
GSK1702934A 8, 23 was prepared according to the method illustrated in scheme 1.
Scheme 1. Synthetic route to GSK1702934A. Reagents and conditions: (i) oxalyl chloride, DMF, DCM, 08C to r.t., 1 h, 80%; (ii) 4-(2-keto-1-benzimidazolinyl) piperidine, DMAP, DCM, 08C to r.t., 15 min, 82%.
Transgenic animal model, functional and biochemical experiments
A transgenic mouse model of cardiac-specific TRPC3 overexpression (low expression line 23; TRPC3-TG), generated by Prof. Molkentin, 9, 10, 17 was compared with age-matched (2-4 months) and sex-matched wildtype (WT) littermate controls (FVB/N strain). Langendorff-perfused whole hearts, 24, 25 electrophysiological recordings in single isolated myocytes, fluo-4 Ca 2+ imaging, western blots, immunocytochemistry, and confocal imaging were performed. Data were subjected to statistical analysis using KaleidaGraph 4.5 and Origin 6.1 software. All substances used were of the highest purity available. Experimental details are provided in an extended methods section in the Supplementary material online.
Results
Selective activation of a TRPC3 conductance in cardiomyocytes
A novel activator of lipid-sensitive TRPC channels, GSK1702934A (GSK), has recently been introduced. 23 Availability of this compound by custom synthesis prompted us to investigate the acute functional consequences of TRPC3 activation in the heart and a scenario lacking phospholipase C stimulation and signalling pathways that hamper evaluation of the exact role of the channel. When challenged with GSK (1 mM), TRPC3-transgenic (TG) cardiomyocytes exhibited a nonselective membrane conductance with features resembling that of heterologously expressed TRPC3 channels. In contrast to control (WT) cardiomyocytes, TRPC3-TG cardiomyocytes displayed the typical double-rectifying characteristics of TRPC3 currents ( Figure 1A ) as previously described for the HEK293 overexpression system. 26 GSK-induced membrane currents in TRPC3-overexpressing HEK293 cells are illustrated for comparison in Figure 1B . 23 Time courses of GSK-sensitive currents were similar in TRPC3-TG cardiomyocytes ( Figure 1A , lower panel) and transiently TRPC3-expressing HEK-293 cells ( Figure 1B , lower panel). Peak currents were typically observed 10-15 s after application of the activator and declined to basal levels within 30 s. Current activation was not suppressed by elevation of the intracellular Ca 2+ buffer (11 mmol/L EGTA; Figure 1A ). GSK-induced currents were strictly dependent on TRPC3 expression, and GSK (1 mM) lacked any effects on major ion conductances, which determine cardiac action potential morphology and excitability such as voltage-gated K + conductances (see Supplementary material online, Figure S1A ), substantiating TRPC3 as the primary target of GSK. Applied at a concentration of 1 mM, the TRPC3 activator transiently but significantly (P , 0.05) prolonged action potential duration (APD 90 ) in TRPC3-overexpressing myocytes from 29.5 + 5.6 to 53.0 + 9.0 ms as shown in Figure 1C and moderately depolarized cells from 275.2 + 1.3 to 271.7 + 2.2 mV (P , 0.05, tested by unpaired t-test). Our initial results on the cardiac action of GSK confirmed this compound as a suitable tool to investigate the acute consequences of enhanced TRPC3 conductances in the heart without overlapping effects on other conductances or activation of the phospholipase C signalling pathway. In parallel experiments, we characterized effects of AngII, a common arrhythmogenic mediator and stimulator of the G q /PLC signalling pathway, and observed an AngII-induced membrane conductance that perfectly resembled the GSK-induced TRPC3 activity in terms of time course and current to voltage relation (see Supplementary material online, Figure S2 ). Consequently, we set out to characterize the implications of the transient TRPC3 current for electrical and mechanical function of murine hearts using the isolated perfused Langendorff preparation.
3.2 TRPC3 activity contributes to control of cardiac contractility and arrhythmogenesis GSK (1 mM) lacked significant effects on contractility of isolated perfused hearts from WT mice, but it generated a clear positive inotropic response in TRPC3-TG hearts ( Figure 2A and see Supplementary material online, Figure S3A ). Figure S4A ). This suggests an involvement of TRPC3 in functional effects of AngII at elevated expression levels of TRPC3. Detailed inspection of LVP twitch traces revealed a higher incidence of arrhythmic events in GSK-exposed hearts from TRPC3-TG (median level 2) compared with WT mice (median level 1; P , 0.1) ( Figure 2B ). WT as well as TRPC3-TG hearts displayed rare isolated arrhythmic events (ventricular or atrial premature beats) in non-stimulated (basal) conditions. 
(Patho)physiological role of cardiac TRPC3
GSK exerted a significant pro-arrhythmic action in TRPC3-TG hearts (basal condition: median level 1 vs. median level 2 during GSK application; P , 0.05), characterized by paired ventricular beats, burst of atrial tachycardia, and cardiac alternans in a majority of experiments. GSK in contrast failed to significantly enhance the burden of arrhythmic events in WT hearts as quantified by an arrhythmia scoring system (basal condition: median level 1 vs. median level 1 during GSK application; P ¼ NS) 27 ( Figure 2B ). In three out of eight TRPC3-TG hearts, short, transient episodes of ventricular tachycardia were induced by GSK (see Supplementary material online, Figure S3B ). Similarly, LVP traces from TRPC3-overexpressing hearts revealed a transient burden of arrhythmic activity during AngII challenge. This was characterized by sustained episodes of bigeminal beats during the positive inotropic phase and episodes of atrial or ventricular tachycardia and ventricular or atrial premature beats during recovery of cardiac function (see Supplementary material online, Figure S4 ). The AngII-induced disturbance of cardiac rhythm increased to Levels 3-4 on the arrhythmia scoring for TRPC3-TG hearts (basal condition: median level 1 vs. median level 4 during GSK application; P , 0.01), while WT hearts lacked significant rhythmical disturbances during AngII perfusion (basal condition: median level 1 vs. median level 2 during GSK application; P ¼ NS) (see Supplementary material online, Figure S4A ).
TRPC3 activity promotes arrhythmias by a mechanism involving cellular Ca 21 handling and NCX1
The arrhythmogenic action of GSK was clearly evident from AP recording in isolated myocytes. Analysis of 10 min continuous recordings during GSK perfusion revealed a higher incidence of arrhythmic depolarizations (early and late afterdepolarizations) in TRPC3-TG compared with WT cardiomyocytes ( Figure 3A and B). It is of note that the effects of AngII in isolated TRPC3-TG cardiomyocytes resembled that of GSK in terms of changes in AP morphology (see Supplementary material online, Figure S4D ). Interestingly, when Ca
was efficiently buffered at diastolic levels by intracellular EGTA (11 mM), which did not prevent TRPC3 currents ( Figure 1A ), arrhythmic activity of GSK was blunted ( Figure 3C ) and prolongation of APD 90 by GSK was barely detectable (see Supplementary material online, Figure S5 ). These results suggest that TRPC3-mediated arrhythmic events and changes in AP morphology are not simply a consequence of the TRPC conductance itself, but it involve a more complex linkage between the TRPC conductance and cellular Ca 2+ handling.
As elevated Ca 2+ i is a well-recognized trigger for NCX-mediated arrhythmic events, 28 -30 we hypothesized a role of distorted Ca 2+ homeostasis and NCX1 function in GSK-induced initiation of arrhythmic events. Detailed analysis of arrhythmic activity revealed that a majority of afterdepolarizations occurred either after complete repolarization or at negative potentials more negative than 250 mV during repolarization (see Supplementary material online, Figure 6 ) and may therefore well be based on NCX-mediated inward currents. 31 Preincubation of TRPC3-TG cardiomyocytes with 10 mM 3 ′ , 4 ′ -dichlorobenzamil hydrochloride (DCB), a pharmacological tool to inhibit NCX forward-mode activity, 32 indeed markedly reduced the number of arrhythmic events evoked by GSK, pointing towards TRPC3-triggered alteration of NCX1 function as the basis of the pro-arrhythmic action of GSK ( Figure 3 ). NCX1 expression was found unchanged in TRPC3-TG and WT cardiomyocytes (see Supplementary material online, Figure S7 ), substantiating a functional link between TRPC3 and NCX1. Signalling crosstalk based on micro/nanodomain organization of the channel in proximity of the transporter has already been demonstrated for cardiovascular cells. 22, 33 We hypothesized that TRPC3 activation may promote NCX operation during action potentials. Initial characterization of the effects of AngII on NCX1 forwardmode activity by tail current analysis revealed that AngII increased NCX-inward currents only in TRPC-TG myocytes (see Supplementary material online, Figure S2C ). To test whether TRPC3 expression and activity indeed determines exchanger operation during cyclic de-and repolarization, we performed patch-clamp experiments in TRPC3-TG cardiomyocytes to delineate cyclic NCX function as the Ni 2+ -sensitive current component ( Figure 4) . These experiments were performed in the absence of functional sarcoplasmic reticulum (SR) using a voltageclamp protocol to quantify reverse-and forward-mode NCX activity during depolarization and subsequent repolarization, respectively. 34, 35 SR function was disrupted with thapsigargin (Tg, 3 mmol/L), and voltagegated Ca 2+ entry was blocked with nitrendipine (10 mM). TRPC3-TG myocytes displayed elevated NCX outward as well as consecutive inward currents compared with wild-type myocytes when applying strong depolarizing voltage steps (+100 mV; Figure 4) . Moreover, NCX currents were significantly amplified by TRPC3 overexpression Figure S8 . Ca 2+ spark frequency was significantly higher in TRPC3-TG than in WT myocytes already at basal levels of TRPC activity ( Figure 5 ). Activation of TRPC3 by GSK (1 mM) clearly increased the frequency of Ca 2+ sparks in TRPC3-TG and promoted Ca 2+ discharge in WT myocytes to a level slightly below that observed in unstimulated TRPC3-TG myocytes. Interestingly, experiments designed to evaluate SR Ca 2+ content did not indicate differences between TRPC3-TG and WT myocytes. Details of the Ca 2+ transients measured in WT and TG myocytes are given in the supplemental information section ( Table 1) . As TRPC3 activation was found to promote both NCX currents and Ca 2+ mobilization from the SR with a considerably prolonged time course compared with that of current activation, we speculated about additional dynamic changes in the TRPC3-NCX crosstalk and set out to investigate localization of the proteins in cardiac myocytes. A close spatial relation between TRPC3 and NCX1 has previously been demonstrated 21, 38 and is considered prerequisite for functional consequences of cardiac TRPC3 activation. We hypothesized that alterations in spatial coupling betweenTRPC3 and NCX1 may be involved in prolongation of functional consequences of TRPC3 activation. In a first set of experiments, we analysed the localization of TRPC3 and NCX1 in TRPC3-TG myocytes by immunocytochemistry ( Figure 6 ). Our results corroborated colocalization of the two transport molecules at basal conditions. Interestingly, activation of TRPC3 channels by GSK effectively disrupted colocalization of the signalling proteins ( Figure 6 ) and a similar effect was initiated by AngII (see Supplementary material online, Figure S9 ). To more directly monitor the disruption of TRPC3-NCX complexes by GSK in cardiac cells, we performed FRET experiments in HL-1 murine atrial myocytes transfected to express fluorescent fusions of NCX1 and TRPC3. Cells expressing equal levels of the fluorescent proteins in the plasma membrane were analysed and displayed significant FRET signals at resting conditions, indicative of direct coupling between the molecules ( Figure 6D) .
Upon exposure to 1 mM GSK, FRET signal abruptly declined to a significantly lower level ( Figure 6E) , substantiating re-localization and dissociation of the molecules after activation of the channel with GSK.
It is tempting to speculate that rapid spatial uncoupling of TRPC3 from NCX will lower local Na + at the exchanger during repolarization, which is expected to impact differentially on reverse and forward-mode operation of NCX, promoting preferentially forward-mode Na + entry. Our results clearly suggest activity-dependent coupling between cardiac TRPC3 and NCX1 ( Figure 7) as a potential mechanism for tuning of TRPC3/NCX1-mediated control of cardiac Ca 2+ homeostasis, contractility, and excitability.
Discussion
Using a murine model of cardiac TRPC3 overexpression and a novel pharmacological tool to directly activate TRPC3 channels, we obtained (Patho)physiological role of cardiac TRPC3 evidence for a Ca 2+ -dependent impact of a non-selective TRPC conductance on cardiac functions. We demonstrate that acute activation of cardiac TRPC3 increases contractility and promotes arrhythmias by a process most likely involving TRPC3/NCX1 interaction. Lipid-regulated TRPC channels are suggested to form a signalling complex with NCX1, which contribute to adaptation of cardiac contractility during remodelling processes and represent a potential player in arrhythmogenesis.
TRPC3 expression and activity determines cardiac contractility and rhythm
Although a pivotal role of lipid-regulated TRPC channels in cardiac hypertrophic remodelling has repeatedly been demonstrated, 40 their impact on contractility and excitability of the heart is still elusive. Judgment of the role of cardiac TRPC channels is generally hampered by high variability of expression levels and by the fact that activation of TRPC conductances by (patho)physiological stimuli is inevitably associated with parallel changes in phospholipid and Ca 2+ signalling, which make clear assignment of functional changes to a TRPC conductance difficult. Understanding of the exact link between TRPC activity and cardiac function is prerequisite for development of pharmacological strategies based on TRPC as target structure. In this study, we took advantage of a model of cardiac-specific overexpression of TRPC3 17 and the availability of a novel small molecule activator of TRPC3 channels. 23 As TRPC3 expression is essentially low in wild-type mice, the organ-specific overexpression model allowed for evaluation of TRPC3 selectivity of the novel activator GSK. The synthetic TRPC3 agonist initiated a conductance with classical TRPC3 features in a strictly TRPC3 expression-dependent manner, indicating selective activation of TRPC3 channels. Consistently, other cardiac conductances or action potential parameters were barely affected by GSK. Although TRPC3 expression in healthy wild-type mice is low, the cation channel is typically up-regulated during maladaptive cardiac remodelling. 1, 15 Thus, the here deployed overexpression model allows for a specific analysis of the functional consequences of TRPC3 up-regulation in the heart. Previous studies questioned an impact of TRPC channels on cardiac excitation-contraction coupling based on a lack of TRPC localization in diade structures and proximity to L-type Ca 2+ channels. 18 Here we demonstrate a transient increase in contractility, associated with arrhythmogenesis as an acute response to direct TRPC3 channel activation. Elevated expression of TRPC3 has previously been reported to lack significant effects on contractility in basal conditions 17 or to even reduce contractility in the absence of TRPC3-activating stimuli using post rest stimulation protocols. 19 The latter effect was observed in Figure 7 . This concept was supported by our observation that TRPC3 overexpression, already at basal levels of channel activity, significantly enhanced discharge of Ca 2+ from the SR.
This effect was further accentuated during activation of channels with GSK and is most likely based not only on Ca 2+ entering through TRPC3 channels but on reduced Ca 2+ extrusion or even reverse-mode Ca 2+ entry at positive potentials ( Figure 7) . Consistently, we observed TRPC3-dependent promotion of cyclic NCX activity in a voltage-clamp protocol (Figure 4) , corroborating the principle of a rather direct modulation of NCX operation by the TRPC3 conductance. Enhanced reversemode currents during strong depolarizing pulses were followed by exaggerated forward-mode operation during subsequent hyperpolarization of TRPC3-overexpressing myocytes. It appears conceivable that activation of a Na + permeable channel in proximity of NCX1 generates a gain in the dynamic function of the exchanger as previously suggested for NaV channels. 43 that may contribute to TRPC3-mediated arrhythmogenesis. Our analysis of subcellular localization of TRPC3 and NCX1 by immunocytochemistry as well as of fluorescent fusion proteins expressed in HL-1 atrial myocytes confirmed colocalization and physical interaction. Importantly, our experiments revealed activity-dependent disruption of local coupling between the TRPC channel and the exchanger. This phenomenon was initiated by channel activation, develops within 2-10 min after agonist stimulation, and is suggested to facilitate NCX-inward currents due to a drop in local Na + at the exchanger. Rapid reduction of Na + entry into a sub-plasmalemmal space of restricted diffusion is expected to affect NCX function during action potentials and to promote late EADs or DADs. This effect may in part involve removal of Na + -dependent inhibition of NCX. 44, 45 It is thus tempting to speculate that this scenario is the basis of transient facilitation of arrhythmogenesis (see scheme in Figure 7) . We suggest a model of cardiac TRPC3-NCX interaction in which NCX function is determined by proximity to TRPC3. At basal levels of TRPC3 activity and spatial coupling between the signalling molecules within a nano/ microdomain, NCX forward mode is limited by local Na + entry.
Along with TRPC3-mediated Ca 2+ entry, this state is proposed to account for enhanced Ca 2+ mobilization from the SR and positive inotropy during channel activation. Abrupt dissociation of TRPC3 from NCX may promote arrhythmic events.
TRPC3-NCX signalplexes as potential therapeutic targets in the myocardium
Lipid-sensitive TRPC3/6/7 channels have recently emerged as potential therapeutic targets for the prevention of cardiac remodelling. Early stages of hypertrophic remodelling have been characterized by enhanced expression of lipid-sensitive TRPC channel complexes, 15 and Ca 2+ entry via these channels has clearly been identified as a signal that triggers Ca 2+ -dependent expression of prohypertrophic genes. 12 Therefore, TRPC channels are proposed as elements of a critical feed-forward process in pathological remodelling, and inhibition of these channels might be considered as a strategy for prevention of heart failure development. It is important to point out that our results were obtained with a murine model of cardiac dysfunction. As this experimental model represents a specific type of cardiac muscle with Ca 2+ handling being different from that in larger rodents or humans, conclusions to human pathology need to be drawn with care. Nevertheless, our current study employing a TRPC3 overexpression model unravels TRPC3 expression as a potential determinant of contractile function and susceptibility to arrhythmogenic stimuli. A recent report attributed the role of cardiac TRPC3 in arrhythmogenesis to the channel's expression in fibroblasts. 46 Here we present evidence that enhanced levels of TRPC3 in cardiomyocytes modify promote arrhythmogenic effects of AngII, which is known to evoke similar electrophysiological effects as GSK in the TRPC3-overexpressing heart. Enhanced cardiac expression of TRPC3 might be beneficial to restore contractility in early stages of remodelling. Excessive activation of the lipid-sensitive cation channels is, however, associated with enhanced arrhythmogenesis and Ca 2+ overload-mediated cardiac dysfunction. This concept opens the view on novel therapeutic strategies based on targeting specific TRPC3 functions or its molecular coupling to NCX1.
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